AstraZeneca cancer drug carries toxic risks: FDA

Nov 30, 2010

An experimental drug developed by AstraZeneca to treat a rare form of thyroid cancer carries "substantial toxicity" risks, the US Food and Drug Administration warned Tuesday.

Thirty-one percent of patients taking the drug, vandetanib, experienced serious side effects compared to 13 percent who did when taking a placebo.

Side effects included a potentially dangerous skin rash known as Stevens-Johnson syndrome, strokes and lung disease.

Many patients involved in studies also had to switch to lower doses, the FDA said in a report ahead of a December 2 meeting of outside experts to discuss the findings and recommend whether the drug should come to market.

Eighty percent of patients in a Phase II study that began with a 300-milligram dose of the drug "required a dose reduction or interruption."

A subsequent study that gave patients a 100-milligram dose saw 21 percent require dosage to be reduced or stopped.

"Given the substantial toxicity seen with vandetanib, should its indication be limited to patients with progressive, symptomatic medullary thyroid cancer?" the FDA asked. "Should additional doses of vandetanib be explored?"

The FDA does not have to follow the expert panel's recommendations but it often does.

expects to have a decision by January on its new drug application for vandetanib in patients with medullary thyroid cancer, a relatively rare disease that typically carries lower survival rates than other forms of .

Some 45,000 new cases are expected to be diagnosed this year in the United States.

The company says the drug works by slowing .

Vandetanib was initially set to be a treatment for but AstraZeneca withdrew its request for the drug to be put on the market for such use in 2009 after studies showed it failed to extend survival rates.

Explore further: Xtoro approved for swimmer's ear

add to favorites email to friend print save as pdf

Related Stories

FDA panel backs Schering-Plough cancer drug

Oct 05, 2009

(AP) -- Federal health advisers voted 6-4 on Monday that the potential benefits of a Schering-Plough drug outweigh its toxic risks as a treatment for late-stage skin cancer.

Experts veto Avastin as a breast cancer treatment

Jul 20, 2010

(AP) -- A panel of cancer experts said Tuesday that the government should remove its endorsement of Roche's drug Avastin for breast cancer, after follow-up studies failed to show benefits for patients.

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

Recommended for you

Xtoro approved for swimmer's ear

10 hours ago

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

11 hours ago

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.